KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt to Equity (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Debt to Equity for 13 consecutive years, with $43.89 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 960.53% to $43.89 in Q4 2025 year-over-year; TTM through Dec 2025 was $43.89, a 960.53% increase, with the full-year FY2025 number at $43.89, up 960.53% from a year prior.
  • Debt to Equity was $43.89 for Q4 2025 at Halozyme Therapeutics, up from $3.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $43.89 in Q4 2025 to a low of $0.03 in Q2 2025.
  • A 5-year average of $7.95 and a median of $4.14 in 2024 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: soared 6495.68% in 2023, then crashed 99.43% in 2025.
  • Halozyme Therapeutics' Debt to Equity stood at $4.45 in 2021, then soared by 99.27% to $8.87 in 2022, then skyrocketed by 101.68% to $17.89 in 2023, then crashed by 76.86% to $4.14 in 2024, then skyrocketed by 960.53% to $43.89 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Debt to Equity are $43.89 (Q4 2025), $3.0 (Q3 2025), and $0.03 (Q2 2025).